Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its wholly-owned subsidiary, Yantai Dongcheng Northern Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of a new specification (0.2ml: 5000AXaIU) for its low molecular heparin product, Dalteparin Sodium Injection [1] Group 1: Product Information - Dalteparin Sodium Injection is a low molecular weight heparin preparation with anticoagulant properties, primarily indicated for the treatment of acute deep vein thrombosis [1] - The product is also used to prevent acute renal failure or chronic renal insufficiency during hemodialysis and blood filtration, as well as to treat unstable coronary artery diseases such as unstable angina and non-Q wave myocardial infarction [1] - Additionally, it is indicated for the prevention of thromboembolism associated with surgical procedures [1]

Core Viewpoint - Jinghua Pharmaceutical (002349) is currently in the process of optimizing the production process for its product Mabalosavir, and it has not yet reached the conditions necessary for commercial production and sales [1] Company Summary - The company is actively working on the process optimization of Mabalosavir [1] - As of now, the product is not ready for commercial production and sales [1]

Group 1 - The company stated that its subsidiary's product, Dioxide Five Ring, is primarily used for the synthesis of co-polymer formaldehyde, with a small portion utilized in lithium iron phosphate battery electrolyte [1] - The pricing of the product is determined based on market demand, and its production and sales volume remain stable [1]

Core Viewpoint - Lu Kang Pharmaceutical (600789) has received a government subsidy of 14,360,000.00 yuan, which is expected to positively impact the company's profits for the fiscal year 2025 [1] Financial Performance - As of December 9, 2025, Lu Kang Pharmaceutical's stock closed at 9.52 yuan, down 1.45% from the previous trading day [1] - The stock opened at 9.67 yuan, reached a high of 9.74 yuan, and a low of 9.51 yuan, with a trading volume of 2.56 billion yuan and a turnover rate of 2.97% [1] - The latest total market capitalization of the company is 85.55 billion yuan [1] Government Subsidy - The government subsidy received by Lu Kang Pharmaceutical accounts for 3.52% of the company's audited net profit for the fiscal year 2024 [1] - The subsidy is categorized as an asset-related government grant, which is anticipated to have a positive effect on the company's profits for the fiscal year 2025 [1] - The final accounting treatment and impact on annual profit and loss will be confirmed by the auditing institution [1]

Core Viewpoint - The launch of the National Medical Insurance Administration's drug price registration system reflects a strong support for pharmaceutical innovation and aims to enhance the modernization of drug price governance in China [1] Group 1: Drug Price Registration System - The new system operates on the principles of "one location for acceptance, nationwide sharing, and global openness," providing drug price registration and inquiry services for domestic and foreign pharmaceutical companies [1] - This initiative is expected to facilitate the international expansion of Chinese innovative drugs and attract high-quality new drugs from abroad into the Chinese market [1] Group 2: Market Dynamics - The importance of China's large-scale market in the global pharmaceutical landscape is increasing, leading to higher demands for improving the drug price governance system [1] - The pharmaceutical industry is experiencing a structural recovery trend, with both supply and demand sides reaching a turning point [1] Group 3: Investment Opportunities - The Guotai Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily fluctuation of up to 20% [1] - This index focuses on innovative pharmaceutical sectors, selecting listed companies with high R&D investment and strong innovation capabilities, reflecting the overall performance of leading companies in the pharmaceutical industry with growth and technological attributes [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.47% on December 9, with the Shanghai Composite Index closing at 3909.52, down 0.37%, and the Shenzhen Component Index at 13277.36, down 0.39% [1] Stock Performance - The leading stock decline was observed in "退市苏吴," which fell by 67.74% to a closing price of 0.40, with a trading volume of 2.0568 million shares and a transaction value of 90.8383 million yuan [1] - Other notable declines included "康艺药业" down 7.85% to 10.80, "母南通的" down 7.67% to 7.82, and "广济药业" down 5.85% to 7.89 [1] Capital Flow Analysis - The chemical pharmaceutical sector saw a net outflow of 6.92 billion yuan from institutional investors, while retail investors contributed a net inflow of 3.85 billion yuan [3] - Specific stocks like "恒瑞医药" had a net inflow of 1.37 billion yuan from institutional investors, while "退市苏吴" saw a net inflow of 383.935 million yuan [3]

Core Viewpoint - The collaboration between Haisheng Pharmaceutical and Hangzhou Advanced Research Institute aims to establish an Advanced Synthesis Technology Industry Research Institute, focusing on the development and industrialization of pharmaceutical raw materials, intermediates, dyes, and new materials, with a total investment of 50 million RMB [1][2]. Group 1 - The partnership is based on principles of complementary advantages, market leadership, openness, fairness, and mutual benefit, leveraging both parties' talent, technology, and resource advantages [1]. - The research direction will emphasize green drug synthesis methods and precise modification of active molecules, contributing to sustainable and efficient synthesis in the pharmaceutical sector [1]. - The collaboration is expected to enhance the company's product variety and reserve, reduce costs, and improve product competitiveness while exploring innovative drugs and biopharmaceuticals [2]. Group 2 - The research team from Hangzhou Advanced Research Institute has published significant academic papers in prestigious journals, supporting the development of safe and economical synthesis methods that could revolutionize traditional high-risk processes [1]. - The agreement aims to cultivate high-quality, skilled application-oriented talents to address challenges in research and production, ultimately improving economic efficiency [2]. - The initiative will also explore the integration of artificial intelligence technology in chemical synthesis, optimizing the company's business structure and promoting long-term strategic planning for sustainable development [2].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient Agomelatine, which is primarily used for treating adult depression [1] Group 1: Company Information - The company involved is Guoyao Modern (国药现代), with its wholly-owned subsidiary Jiangsu Weichida Pharmaceutical Co., Ltd. (国药江苏威奇达) receiving the approval [1] - Agomelatine acts on melatonin receptors MT1 and MT2 and antagonizes 5-HT2C, helping to restore disrupted biological rhythms and exerting antidepressant effects [1] Group 2: Product Information - The clinical application of Agomelatine is mainly for the treatment of adult depression [1]

人民财讯12月9日电，海翔药业（002099）12月9日公告，12月8日，公司与国科大杭州高等研究院(简 称"杭高院")签署了《共建先进合成技术产业研究院合作协议》，双方将共同组建先进合成技术产业研 究院。产业研究院的研发方向主要聚焦医药原料药、中间体、染料、新材料的开发与工业化等，合作总 金额5000万元。张夏衡团队是杭高院化学与材料科学学院的研究团队，其新成果在2025年10月发表于 《Nature》，提出了一种安全、经济的芳香胺直接脱氨官能团化方法，颠覆了传统高风险工艺，为传统 上广泛使用却因易爆性和高风险而受限的芳基重氮化学提供了一种安全、经济的新方案，有望在制药、 染料、材料制造等多个重要领域获得广泛应用。 ...

智通财经APP讯，海翔药业(002099.SZ)公告，公司与国科大杭州高等研究院(简称"杭高院")签署了《共 建先进合成技术产业研究院合作协议》，产业研究院的研发方向主要聚焦医药原料药、中间体、染料、 新材料的开发与工业化等，合作总金额5000万元。 ...